OBJECTIVE Currently, there are two categories of epidermal growth factor receptor (EGFR) antagonists, small molecule antagonists and anti-EGFR antibodies. In the current study, we developed a new EGFR antagonist employing the anti-idiotypic antibodies strategy. RESULTS First, using EGF as an antigen, through a series of immunological protocols and hybridoma technology, we obtained an anti-idiotypic antibody against EGF receptor-binding epitopes. On this basis, we screened and characterized the anti-idiotype antibodies against EGFR through competitive ELISA, co-localization analysis, competitive receptor binding analysis, and immunofluorescence. Finally, an internal image anti-idiotype antibody called FG8 was successfully prepared. Experiment result shows that FG8 inhibits EGFR-mediated signaling pathways in vitro. Additionally, FG8 inhibits liver tumor cell proliferation as well as induces tumor cell apoptosis. CONCLUSIONS The present study suggests that FG8 is a potential therapeutic agent for liver cancer. In addition, this study provides a novel method for the preparation of EGFR antagonists.

中文翻译：

---

EGFR 抗独特型抗体拮抗剂 (FG8) 的制备和鉴定，具有抗肝癌细胞的潜在活性

目的目前，表皮生长因子受体（EGFR）拮抗剂有小分子拮抗剂和抗EGFR抗体两大类。在目前的研究中，我们使用抗独特型抗体策略开发了一种新的 EGFR 拮抗剂。结果 首先，以EGF为抗原，通过一系列免疫学方案和杂交瘤技术，我们获得了针对EGF受体结合表位的抗独特型抗体。在此基础上，我们通过竞争性ELISA、共定位分析、竞争性受体结合分析和免疫荧光筛选和表征了针对EGFR的抗独特型抗体。最后，成功制备了一种名为FG8的内像抗独特型抗体。实验结果表明，FG8在体外抑制EGFR介导的信号通路。此外，FG8抑制肝肿瘤细胞增殖并诱导肿瘤细胞凋亡。结论 本研究表明 FG8 是一种潜在的肝癌治疗剂。此外，本研究为EGFR拮抗剂的制备提供了一种新方法。